Amgen owes $406 million for monopolizing cholesterol drug market, US jury says

Source: Reuters

Amgen owes $406 million for monopolizing cholesterol drug market, US jury says

Blake Brittain
Thu, May 15, 2025 at 4:57 PM EDT 1 min read

(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's rival drug Praluent.

The jury agreed with Regeneron that Amgen unlawfully bundled Repatha with two of its blockbuster anti-inflammatory drugs to persuade pharmacy benefit managers to buy it instead of Praluent.

The verdict includes $271.2 million for Regeneron in punitive damages. Amgen said in a statement that it "has always competed fairly and in compliance with the antitrust laws" and "look[s] forward to post-trial proceedings."

-snip-

Read more: https://www.yahoo.com/news/amgen-owes-406-million-monopolizing-205704976.html